Shanghai Mabgeek Biotech.Co.Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-37
RECRUITING4
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MG-K10 NCT06765005 |
P1/2 | Recruiting | Atopic Dermatitis | 24 | 2025-05 |
| MG-K10 Humanized Monoclonal Antibody Injection NCT06846385 |
P2/3 | Recruiting | Seasonal Allergic Rhinitis | 160 | 2025-05-31 |
| MG-ZG122 Humanized Monoclonal Antibody Injection NCT07054034 |
P2 | Active, not recruiting | Bronchial Asthma | 160 | 2026-05-26 |
| NCT06779136 NCT06779136 |
P3 | Recruiting | Prurigo Nodularis | 160 | 2026-08 (+1 mo) |
| MG-K10 Injection (Humanized Monoclonal Antibody) NCT07540442 |
P3 | Not yet recruiting | Dermatitis, Atopic | 180 | 2027-01-05 |
| MG-K10 Injection NCT07838727 |
P2 | Not yet recruiting | Chronic Urticaria, Idiopathic | 60 | 2027-05-07 |
| NCT06837922 NCT06837922 |
P3 | Recruiting | Asthma | 504 | 2027-11-15 (+5 mo) |
| Emollient (moisturizer) NCT07938606 |
P1/2 | Not yet recruiting | Atopic Dermatitis | 24 | 2027-12 |
| MG-K10 NCT07903194 |
P3 | Not yet recruiting | Chronic Rhinosinusitis With Nasal Polyps | 210 | 2027-12-21 |
| MG-K10 Humanized Monoclonal Antibody Injection NCT07546487 |
P3 | Not yet recruiting | Chronic Spontaneous Urticaria (CSU) | 226 | 2028-03-31 |
| ADaggio NCT07479615 |
P3 | Not yet recruiting | Atopic Dermatitis; Atopic Eczema | 498 | 2029-01 |